QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
NASDAQ:LOGC

LogicBio Therapeutics (LOGC) Stock Forecast, Price & News

$0.42
-0.01 (-2.30%)
(As of 05/17/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.41
$0.45
50-Day Range
$0.38
$0.78
52-Week Range
$0.34
$5.19
Volume
417,362 shs
Average Volume
1.03 million shs
Market Capitalization
$14.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.51
30 days | 90 days | 365 days | Advanced Chart
Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LogicBio Therapeutics logo

About LogicBio Therapeutics

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Headlines

LogicBio Says FDA Lifts Clinical Hold On LB-001 IND
Clinical Development Update from Portfolio Company LogicBio
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LOGC
Fax
N/A
Employees
62
Year Founded
N/A

Sales & Book Value

Annual Sales
$5.41 million
Book Value
$0.93 per share

Profitability

Net Income
$-40.03 million
Net Margins
-739.91%
Pretax Margin
-740.42%

Debt

Price-To-Earnings

Miscellaneous

Free Float
30,722,000
Market Cap
$14.01 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/16/2022
Today
5/17/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.82 out of 5 stars

Medical Sector

783rd out of 1,426 stocks

Biological Products, Except Diagnostic Industry

123rd out of 210 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

Is LogicBio Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LogicBio Therapeutics stock.
View analyst ratings for LogicBio Therapeutics
or view top-rated stocks.

Are investors shorting LogicBio Therapeutics?

LogicBio Therapeutics saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 50,000 shares, a decline of 60.9% from the April 15th total of 127,800 shares. Based on an average daily trading volume, of 1,230,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.3% of the shares of the stock are short sold.
View LogicBio Therapeutics' Short Interest
.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for LogicBio Therapeutics
.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Monday, May, 16th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. LogicBio Therapeutics had a negative net margin of 739.91% and a negative trailing twelve-month return on equity of 95.00%.
View LogicBio Therapeutics' earnings history
.

What price target have analysts set for LOGC?

5 analysts have issued twelve-month target prices for LogicBio Therapeutics' stock. Their forecasts range from $6.00 to $16.00. On average, they expect LogicBio Therapeutics' stock price to reach $11.25 in the next year. This suggests a possible upside of 2,547.1% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are LogicBio Therapeutics' key executives?
LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau M.B.A., Pres, CEO & Director (Age 55, Pay $677.2k) (LinkedIn Profile)
  • Dr. Mark A. Kay M.D., Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 63, Pay $85k)
  • Ms. Mariana Nacht Ph.D., Chief Scientific Officer (Age 58, Pay $429.64k)
  • Dr. Kyle Chiang Ph.D., Consultant (Age 42, Pay $348.85k)
  • Dr. Leszek Lisowski M.B.A., Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Adi Barzel Ph.D., Co-Founder
  • Ms. Cecilia Jones, Chief Financial Officer (Age 47)
  • Dr. Matthias Hebben, Global VP & Head of Technology Devel.
  • Ms. Andrea Paul, Gen. Counsel & Corp. Sec.
  • Ms. Grace Lochhead, VP & Head of HR
What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.39%), Vanguard Group Inc. (0.98%), Harbor Capital Advisors Inc. (0.69%), Virtu Financial LLC (0.22%), Acadian Asset Management LLC (0.15%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own LogicBio Therapeutics stock include Bioscience Plc Arix, Daniel Gruskin, Frederic Chereau, Kyle Chiang and Orbimed Advisors Llc.
View institutional ownership trends for LogicBio Therapeutics
.

Which major investors are selling LogicBio Therapeutics stock?

LOGC stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Harbor Capital Advisors Inc., and Simplex Trading LLC.
View insider buying and selling activity for LogicBio Therapeutics
or view top insider-selling stocks.

Which major investors are buying LogicBio Therapeutics stock?

LOGC stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for LogicBio Therapeutics
or or view top insider-buying stocks.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $0.43.

How much money does LogicBio Therapeutics make?

LogicBio Therapeutics has a market capitalization of $14.01 million and generates $5.41 million in revenue each year. The company earns $-40.03 million in net income (profit) each year or ($1.240010) on an earnings per share basis.

How many employees does LogicBio Therapeutics have?

LogicBio Therapeutics employs 62 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is www.logicbio.com.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at (617) 245-0399 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.